Brought to you by 
Genzyme Genetics sublicenses EGFR mutation assay to Roche
Dec 2010
Executive Summary
Genzyme Genetics (recently acquired by LabCorp) has sublicensed to Roche a diagnostic assay that detects mutations in the epidermal growth factor receptor (EGFR) gene. Roche has worldwide rights.
Deal Industry
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Pharmaceuticals
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme Genetics sublicenses EGFR mutation assay to Roche
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice